Recently, recombinant human LCAT injections and gene therapy aim to improve plasma lipid metabolism by increasing LCAT activity carried out with promising results which provided better treatment options for patients with LCAT deficiency (Yang et al., 2022). Here, LCAT is linked to hyperinsulinemic hypoglycemia, familial, 4.